Persistence of HIV-1 transcription in peripheral-blood mononuclear cells in patients receiving potent antiretroviral therapy.

Department of Pathology, Northwestern University Medical School, Chicago, IL 60611, USA.
New England Journal of Medicine (Impact Factor: 54.42). 06/1999; 340(21):1614-22. DOI: 10.1056/NEJM199905273402102
Source: PubMed

ABSTRACT Although potent antiretroviral therapy can control infection with human immunodeficiency virus type 1 (HIV-1), a long-lived reservoir of infectious virus persists in CD4+ T cells. We investigated this viral reservoir by measuring the levels of cell-associated viral DNA and messenger RNA (mRNA) that are essential for HIV-1 replication. Approximately every 6 months, we obtained samples of peripheral-blood mononuclear cells from five men with long-standing HIV-1 infection who had had undetectable levels of plasma HIV-1 RNA for 20 months or more during treatment with potent antiretroviral drugs.
Before treatment, plasma levels of HIV-1 RNA correlated with the levels of cell-associated unintegrated HIV-1 DNA and unspliced viral mRNA. After treatment, plasma levels of HIV-1 RNA fell by more than 2.7 log to undetectable levels. The decrease in cell-associated integrated and unintegrated HIV-1 DNA and mRNA occurred in two phases. The first phase occurred during the initial 500 days of treatment and was characterized by substantial decreases in the levels of DNA and mRNA, but not to undetectable levels. The concentrations of cell-associated unintegrated viral DNA, integrated proviral DNA, and unspliced viral mRNA decreased by 1.25 to 1.46 log. The second phase occurred during the subsequent 300 days or more of treatment and was characterized by a plateau in the levels of HIV-1 DNA and unspliced mRNA. After an initial rapid decline, the ratio of unspliced to multiply spliced viral mRNA (a measure of active viral transcription) stabilized and remained greater than zero at each measurement.
Despite treatment with potent antiretroviral drugs and the suppression of plasma HIV-1 RNA to undetectable levels for 20 months or more, HIV-1 transcription persists in peripheral-blood mononuclear cells. Unless the quasi-steady state levels of HIV DNA and mRNA eventually disappear with longer periods of therapy, these findings suggest that HIV-1 infection cannot be eradicated with current treatments.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Plasma viral load and CD4 counts are effective for clinical monitoring, but they do not give a full representation of HIV-1 quasispecies in cellular reservoirs, the major repository of replication-competent HIV-1 in infected individuals. We sought to develop a diagnostic system that could stimulate the replication- competent HIV-1 reservoirs for enhanced clinical monitoring including selection of antiretroviral regimens. Whole blood from 45 HIV-infected individuals was collected into 1 ViraStim™ HIV-1 activation tube and 1 EDTA tube. Samples were tested for viral load and cell-type specific HIV-1 replication. Further, 7 matched activated/non-activated samples were sequenced using the TRUGENE® HIV-1 Genotyping Kit. The percentage of patients with replication-competent virus in PBMCs varied depending on the baseline plasma viral load in the EDTA tubes. Six out of 24 patients with starting plasma viral load<20 copies/mL (cp/mL), 6 out of 8 patients with starting viral loads >20 and <1000 cp/mL, and 8 patients out of 13 with starting viral loads >1000 all showed an increase in viral replication greater than 5-fold. This increase came from cellular reservoirs in blood as determined by Simultaneous Ultrasensitive Subpopulation Staining/Hybridization In Situ (SUSHI). When comparing resistance genotypes in plasma from activation tubes compared to EDTA tubes for 7 patients, all patients showed additional mutations in the activation tube, while 3 patients demonstrated additional genotypic resistance determinants compared to EDTA tubes. We show that HIV-1 viral replication can be stimulated directly from infected whole blood. The sequencing results showed 3 of 7 cases demonstrated additional drug resistance following stimulation.
    Journal of Clinical Microbiology 10/2014; 53(1). DOI:10.1128/JCM.02539-14 · 4.23 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Based on heterogeneities in drug efficacy (either spatial or phenotypic), two HIV compartmental models were proposed in Callaway and Perelson (2002) to study the HIV virus dynamics under drug treatment. In this paper, we provide a global analysis on the two models, including the positivity and boundedness of solutions and the global stability of equilibrium solutions. In particular, we show that when the basic reproduction number (for which the infection equilibrium does not exist), the infection-free equilibrium is globally asymptotically stable; while when (for which the infection equilibrium exists), the infection equilibrium is globally asymptotically stable.
    Communications in Nonlinear Science and Numerical Simulation 06/2015; DOI:10.1016/j.cnsns.2014.11.001 · 2.57 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Apathy remains a common neuropsychiatric disturbance in the Human Immunodeficiency Virus (HIV-1) despite advances in anti-retroviral treatment (ART). The goal of the current review is to recapitulate findings relating apathy to the deleterious biobehavioral effects of HIV-1 in the post-ART era. Available literatures demonstrate that the emergence of apathy with other neurocognitive and neuropsychiatric symptoms may be attributed to neurotoxic effects of viral proliferation, e.g., aggregative effect of Tat and gp120 on apoptosis, transport and other enzymatic reactions amongst dopaminergic neurons and neuroglia. An assortment of neuroimaging modalities converge on the severity of apathy symptoms associated with the propensity of the virus to replicate within frontal-striatal brain circuits that facilitate emotional processing. Burgeoning research into functional brain connectivity also supports the effects of microvascular and neuro-inflammatory injury linked to aging with HIV-1 on the presentation of neuropsychiatric symptoms. Summarizing these findings, we review domains of HIV-associated neurocognitive and neuropsychiatric impairment linked to apathy in HIV. Taken together, these lines of research suggest that loss of affective, cognitive and behavioral inertia is commensurate with the neuropathology of HIV-1. Copyright © 2015. Published by Elsevier Ltd.
    Neuroscience & Biobehavioral Reviews 05/2015; DOI:10.1016/j.neubiorev.2015.04.008 · 10.28 Impact Factor